Clinical Trials Logo

Filter by:
NCT ID: NCT04788017 Completed - Healthy Subjects Clinical Trials

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

Start date: March 24, 2021
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ziresovir following a single ascending oral dose administration in healthy adult subjects under fasted conditions.

NCT ID: NCT04787978 Completed - Hypertension Clinical Trials

Creating Healthier Communities Through Meaningful Partnerships: A Model From the National African American Male Wellness Initiative - OSU Partnership

Start date: February 29, 2020
Phase: N/A
Study type: Interventional

Primary Objective: Test feasibility and acceptability of a 24-week community-based lifestyle intervention to improve cardiovascular health among African American males. Secondary Objectives: 1) Navigate participants to establish primary care and address social and patient activation needs that present barriers to wellness; 2) Examine changes in cardiovascular health as per American Heart Association Life's Simple 7 Metrics including blood pressure, cholesterol, glucose, smoking, body mass index, physical activity and dietary intake (1); and 3) Increase African American male participation in clinical trials.

NCT ID: NCT04787965 Completed - Parkinson Disease Clinical Trials

Opicapone Treatment Initiation Open-Label Study

OPTI-ON
Start date: March 1, 2021
Phase:
Study type: Observational

This is an observational study to describe the treatment patterns and clinical outcomes observed with use of ONGENTYS as adjunctive treatment to levodopa/carbidopa in Parkinson's disease patients experiencing "off" episodes with motor fluctuations

NCT ID: NCT04787718 Completed - Muscle Soreness Clinical Trials

Almond for Physical Performance

Start date: July 15, 2020
Phase: N/A
Study type: Interventional

Investigators specific aims are to compare the effects of consuming daily snacks of raw, shelled, unsalted almonds (2.0 ounces) versus an isocaloric amount of another commonly consumed snack food (pretzels) on energy (vigor) perception and physical activity, exercise performance (VO2max and measures of strength), strength and power performance as well as muscle soreness recovery after strenuous eccentrically-biased exercise.

NCT ID: NCT04787692 Completed - Clinical trials for Elective Spine Surgery Receiving Pre and/or Postoperative Pain Control With Opioids

Impact of Daily, Digital and Behavioral Tele-health Tapering Program for Perioperative Surgical Patients Exposed to Opioids and Benzodiazepines.

Start date: August 7, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the safety, acceptability, and feasibility of a controlled taper off of opioids and/or benzodiazepines, with the use of behavioral health tele-health based therapy services, in the perioperative patient.

NCT ID: NCT04787614 Completed - Child Care Clinical Trials

2019 NSECE COVID-19 Follow-up

Start date: November 1, 2020
Phase:
Study type: Observational

The objective of the National Survey of Early Care and Education (NSECE) is to document the nation's current supply of early care and education (ECE) services. Because the COVID-19 pandemic is likely to have had an impact on the ECE supply, and because the availability of ECE services is critical to restoring the U.S. economy, updated data on the ECE supply will be crucial for policy-making and research. The purpose of the NSECE COVID-19 Follow-up Study is to describe the impact of the COVID-19 pandemic on the pre-pandemic ECE supply and the ECE workforce, including changes in supply or departures from and re-entries to the workforce. Data from the study can be used to estimate the impact of the pandemic on ECE supply and the financial health of ECE providers, as well as providers' experiences during and after the pandemic emergency. Through a two-wave design, the NSECE COVID-19 Follow-up Study data will trace providers' and workforce members' experiences from 2019, through the initial months of the pandemic (to be reported in the Wave 1 interview), and then to the one-year point since the onset of the pandemic (to be reported in the Wave 2 interview). This design is intended to capture the trajectories of providers and workforce members, for example through recovery back to full or modified participation in ECE supply, or long-term exits from ECE supply. Prospectively collecting these data allows inference about the types of providers and workforce members most likely to have exited or survived in ECE, as well as the programmatic supports received by those who remain in ECE at the time of the second interview.

NCT ID: NCT04787562 Completed - Clinical trials for Bacterial Infections

Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function

Start date: February 25, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label study to assess the PK, safety and tolerability of XNW4107, imipenem and cilastatin administered by 60-minute (60-min) IV infusion to adults with various degrees of renal insufficiency as compared to subjects with normal renal function.

NCT ID: NCT04787445 Completed - Clinical trials for Pulmonary Arterial Hypertension

Effects of Pulmonary Hypertension Therapy in Atypical Pulmonary Arterial Hypertension

Start date: March 11, 2021
Phase:
Study type: Observational

The purpose of this study is to characterize the clinical and hemodynamic response of Pulmonary Arterial Hypertension (PAH) therapy in patients with atypical PAH and risk factors for left heart disease.

NCT ID: NCT04787367 Completed - Obesity Clinical Trials

Laparoscopic TAP Block for Sleeve Gastrectomy: Does Timing Matter

Start date: February 12, 2019
Phase: N/A
Study type: Interventional

The goal of this study is to investigate whether an early intraoperative transverse abdominis plane block (TAP block) will provide superior analgesia to a late intraoperative TAP block. A fixed amount of bupivacaine will be used for the TAP block and the primary outcomes will be measured by patient reported numerical assessment scores for pain.

NCT ID: NCT04787302 Completed - Schizophrenia Clinical Trials

PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

Start date: June 1, 2021
Phase: Phase 1
Study type: Interventional

PET Trial to Evaluate Target Occupancy of CVL-231 at Muscarinic Receptors Type 4 in Brain Following Oral Dosing